Business Wire

ForumPay Joins Forces with ZBX to Bring Crypto Payments to Malta’s Gaming Industry

16.8.2021 14:07:00 EEST | Business Wire | Press release

Share

ForumPay, the global cryptocurrency payments technology provider is delighted to announce a partnership with ZBX, the Maltese crypto exchange to enable the 250 million plus crypto wallet holders around the world to use their crypto for deposits with local iGaming sites.

The partnership with ZBX, a Class 4 VFA Service Provider with the MFSA (Malta Financial Services Authority) enables ForumPay to offer the first fully compliant crypto payments solution for MGA (Malta Gaming Authority) licensed gaming operators and their players.

Thanks to this collaboration, the depositing experience is even easier than using a credit card. To make a deposit with their favorite crypto and wallet a player simply scans the QR code presented in the online cashier. The crypto is instantly converted into FIAT at the best available exchange rate for deposit into the player’s account.

After this quick step, the iGaming site will automatically be notified of the crypto equivalent in FIAT awarded to the player so that they can access the funds immediately for play. This hassle-free process is a major milestone for crypto adoption in the gaming world, as it lets crypto holders convert just the amount they plan on betting with.

The tie up comes after the executive teams of both companies spent time with the regulators to establish a crypto payments flow which is sensitive to the KYC and AML demands on the gaming operators and meets the requirements of the MGA and MFSA.

Josh Tate, CEO and co-founder of ForumPay said, “It is exciting to work with such innovative companies and regulators to meet a massive demand in the marketplace from both operators and players. Facilitating crypto payments in the iGaming space has major benefits, such as amplifying the player base, fraud protection for casinos through instant verification of funds, and paving the way for the mass adoption of cryptocurrency in a fully compliant environment.”

Ian Dawson, CFO of ZBX said, “We are privileged to be a part of the growing crypto iGaming ecosystem in Malta. It is exciting for us to explore the full use cases of both our technology and the VFA Act in the provision of fiat-crypto solutions with ForumPay. We fully expect that the harmonization of crypto technology, regulation and services will improve and increase, and we look forward to working with world leading businesses in the provision of our services.”

ForumPay is a complete cryptocurrency to fiat payment technology firm. Our core processing technology helps businesses attract new customers, optimize customer’s ability to spend and increase revenue by embracing the 250+ million crypto consumers around the world. Our wallet agnostic solution enables the entire crypto consumer community to spend with their preferred cryptocurrency and from their preferred wallet for everyday goods and services. Our services eliminate the merchant’s exposure or risk by processing the transaction with instant conversion of the crypto into traditional currency. Our merchants simply receive their payments in the currency of their choice directly into their preferred bank account. The transactional experience is the same as accepting credit cards or other popular payment options, but simpler, faster, and more secure.

In today’s competitive environment, ForumPay is an excellent tool for businesses to gain a serious competitive advantage with the fastest growing consumer segment in the world. There were more than 5.6 million wallets downloaded in January of this year alone. Studies show that 40% of the consumers that spend crypto with merchants are in fact new customers, hence our characterization of ForumPay as a customer acquisition tool. Additionally, crypto consumers are shown to spend 2x AOV that of a typical credit card consumer illustrating the attractive, affluent demographic.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paul Wordsworth – Director of Global Account Management
paul@forumpay.com

Joaquín de Miguel – Marketing Director at ForumPay
joaquin@forumpay.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye